Clinical case of rhino-orbital mucormycosis in a convalescent COVID-19 patient: diagnostic and treatment tactics
- Authors: Popova A.Y.1, Demina Y.V.1, Zaytseva N.N.2, Kucherenko N.S.3, Denisenko A.N.4, Tochilina A.G.2, Belova I.V.2, Belozerov G.A.4, Polyanina A.V.2, Sadykova N.A.3, Soloveva I.V.2
-
Affiliations:
- Federal Service for Surveillance on Consumer Rights Protection and Human Wellfare
- Academician I.N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology
- Department of the Federal Service for Surveillance on Consumer Rights Protection and Human Welfare in Nizhny Novgorod region
- City Hospital No. 35 of the Sovetsky District of Nizhny Novgorod
- Issue: Vol 12, No 4 (2022)
- Pages: 790-797
- Section: FOR THE PRACTICAL PHYSICIANS
- URL: https://bakhtiniada.ru/2220-7619/article/view/119160
- DOI: https://doi.org/10.15789/2220-7619-CCO-1961
- ID: 119160
Cite item
Full Text
Abstract
According to current data, SARS-CoV-2 virus has the ability to cause multi-organ pathology, leading to acute damage of various organs and systems and long-term consequences characterized by polymorphic symptoms. Recently, a high incidence of invasive mycoses, particularly mucormycosis — COVID-M, has been noted among the COVID-19 complications. The predisposing factor for the development of this pathology is diabetes mellitus, immunodeficiency states, and prolonged use of high doses of glucocorticosteroids. Mucormycosis is characterized by severe clinical manifestations and high lethality, and timely diagnostics of this pathology often represents a difficult problem. The aim of this study was to analyze a clinical case of rhino-orbital mucormycosis in convalescent COVID-19 patient. In the study, there was used mucopurulent nasal discharge from the patient previously hospitalized with a severe novel coronavirus infection. Here, we describe the methodology allowing to isolate and identify a pure mold fungus culture from the biomaterial using methods of routine bacteriology and MALDI-ToF mass spectrometry. Direct microscopy examination of nasal cavity discharge revealed branched non-septic hyphae with a characteristic branching angle, allowing to preliminarily diagnose invasive mucormycosis. Growth of mycelial fungus colony was observed by using Sabouraud’s medium with potassium tellurite. Microscopy of the pure culture revealed branching mycelium without septa, broad, with irregular thickness, unsegregated hyphae, and sporangia with a typical column specific to mucormycetes. Analysis of the obtained mass spectra allowed to establish the microbial species identity as Lichtheimia corymbifera. The latter along with other members of the order Mucorales, are known to cause mucormycosis. As a result of antifungal treatment (Amphotericin B) and timely surgical intervention, the patient was discharged from the hospital with prominent clinical improvement and no complaints during further outpatient follow-up period. The analysis of this clinical case showed the lack of alertness in some clinical diagnostic laboratories to detect pathogens of invasive mycoses. To avoid errors, while making a diagnosis, attention should be paid not only to detection of fungal spores in clinical material, but also take into account the structure of mycelium underlying major difference between yeast-like fungi, higher and lower molds. The isolation and identification of a pure pathogen culture allows to confidently verify the diagnosis, timely correct the treatment tactics and monitor circulation of mycotic agents to prevent occurrence of mycoses in most vulnerable patients cohorts.
Full Text
##article.viewOnOriginalSite##About the authors
Anna Yu. Popova
Federal Service for Surveillance on Consumer Rights Protection and Human Wellfare
Email: depart@gsen.ru
hD, MD (Medicine), Professor, Head
Russian Federation, MoscowYulia V. Demina
Federal Service for Surveillance on Consumer Rights Protection and Human Wellfare
Email: deminajv@gsen.ru
PhD, MD (Medicine), Professor, Head of the Department of Epidemiological Surveillance
Russian Federation, MoscowNatalya N. Zaytseva
Academician I.N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology
Email: zaytseva@nniiem.ru
PhD, MD (Medicine), Director
Russian Federation, 71, Malaya Yamskaya str., Nizhny Novgorod, 603950Natalya S. Kucherenko
Department of the Federal Service for Surveillance on Consumer Rights Protection and Human Welfare in Nizhny Novgorod region
Email: sanepid@sinn.ru
Head of the Department
Russian Federation, Nizhny NovgorodArkadyi N. Denisenko
City Hospital No. 35 of the Sovetsky District of Nizhny Novgorod
Email: host35@inbox.ru
PhD (Medicine), Head
Russian Federation, Nizhny NovgorodAnna G. Tochilina
Academician I.N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology
Author for correspondence.
Email: lab-lb@yandex.ru
PhD (Biology), Senior Researcher, Laboratory of a Human’s Microbiome and Means of its Correction
Russian Federation, 71, Malaya Yamskaya str., Nizhny Novgorod, 603950Irina V. Belova
Academician I.N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology
Email: lab-lb@yandex.ru
PhD (Medicine), Leading Researcher, Laboratory of a Human’s Microbiome and Means of its Correction
Russian Federation, 71, Malaya Yamskaya str., Nizhny Novgorod, 603950Grigoryi A. Belozerov
City Hospital No. 35 of the Sovetsky District of Nizhny Novgorod
Email: host35@inbox.ru
Head of the Otorhinolaryngological Department
Russian Federation, Nizhny NovgorodAnastasia V. Polyanina
Academician I.N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology
Email: polyanina.anastasia@yandex.ru
PhD (Medicine), Deputy Director
Russian Federation, 71, Malaya Yamskaya str., Nizhny Novgorod, 603950Natalya A. Sadykova
Department of the Federal Service for Surveillance on Consumer Rights Protection and Human Welfare in Nizhny Novgorod region
Email: sanepid@sinn.ru
Deputy Head
Russian Federation, Nizhny NovgorodIrina V. Soloveva
Academician I.N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology
Email: lab-lb@yandex.ru
PhD, BD (Biology), Associate Professor, Leading Researcher, Head of the Laboratory of the Human Microbiome and Means of its Correction
Russian Federation, 71, Malaya Yamskaya str., Nizhny Novgorod, 603950References
- Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 15 от 22.02.2022. М., 2022. 233 с. [Interim guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 15 dated 22.02.2022. Moscow, 2022. 233 p. (In Russ.)]
- Долгополов И.С., Менткевич Г.Л., Рыков М.Ю., Чичановская Л.В. Неврологические нарушения у пациентов с long COVID синдромом и методы клеточной терапии для их коррекции: обзор литературы // Сеченовский вестник. 2021. Т. 12, № 3. С. 56–67. [Dolgopolov I.S., Mentkevich G.L., Rykov M.Yu., Chichanovskaya L.V. Neurological disorders in patients with long COVID syndrome and cell therapy methods for their correction: a literature review. Sechenovskii vestnik = Sechenov Medical Journal, 2021, vol. 12, no. 3, pp. 56–67. (In Russ.)] doi: 10.47093/2218-7332.2021.12.3.56-67
- Древаль А.В., Губкина В.А., Камынина Т.С., Лосева В.А., Мельникова Е.В., Зенгер В.Г., Ашуров З.М., Исаев В.М., Слоева А.И., Макаренко М.Ф., Рябцева А.А., Лучков М.Ю., Крючкова Г.С. Три случая мукормикоза у больных сахарным диабетом (Московская область) // Проблемы эндокринологии. 2004. Т. 50, № 5. С. 39–44. [Dreval’ A.V., Gubkina V.A., Kamynina T.S., Loseva V.A., Mel’nikova E.V., Zenger V.G., Ashurov Z.M., Isaev V.M., Sloeva A.I., Makarenko M.F., Ryabtseva A.A., Luchkov M.Yu., Kryuchkova G.S. Three cases of mucoromycosis in patients with diabetes mellitus (Moscow Region). Problemy endokrinologii = Problems of Endocrinology, 2004, vol. 50, no. 5, pp. 39–44. (In Russ.)] doi: 10.14341/probl11524
- Кашкин П.Н., Хохряков М.К., Кашкин А.П. Определитель патогенных, токсигенных и вредных для человека грибов. Л.: Медицина, 1979. 272 с. [Kashkin P.N., Khokhryakov M.K., Kashkin A.P. Identifier of pathogenic, toxigenic and harmful fungi for humans. Leningrad: Medicine, 1979. 272p. (In Russ.)]
- Клиническая микробиология: руководство для специалистов клинической лабораторной диагностики. М.: ГЭОТАР-Медиа, 2011. 480 с. [Clinical microbiology: a guide for clinical laboratory diagnostics specialists. Moscow: GEOTAR-Media, 2011. 480 p. (In Russ.)]
- Лебедева М.Н. Руководство к практическим занятиям по медицинской микробиологии. М.: Медицина, 1973. 312 с. [Lebedeva M.N. Handbook for practical training in medical microbiology. Moscow: Medicine, 1973. 312 p. (In Russ.)]
- Тараскина А.Е., Пчелин И.М., Игнатьева С.М., Спиридонова В.А., Учеваткина А.Е., Филиппова Л.В., Фролова Е.В., Васильева Н.В. Молекулярно-генетические методы определения и видовой идентификации грибов порядка Mucorales в соответствии с глобальными рекомендациями по диагностике и терапии мукоромикоза (обзор литературы) // Проблемы медицинской микологии. 2020. Т. 22, № 1. С. 3–14. [Taraskina A.E., Pchelin I.M., Ignat’eva S.M., Spiridonova V.A., Uchevatkina A.E., Filippova L.V., Frolova E.V., Vasil’eva N.V. Molecular genetic methods for detection and species identification of fungal order Mucorales in accordance with the global guideline for the diagnosis and management of mucoromycosis (literature review). Problemy meditsinskoi mikologii = Problems in Medical Mycology, 2020, vol. 22, no. 1, pp. 3–14. (In Russ.)] doi: 10.24412/1999-6780-2020-1-3-14
- Хостелиди С.Н., Зайцев В.А., Пелих Е.В., Яшина Е.Ю., Родионова О.Н., Богомолова Т.С., Авдеенко Ю.Л., Климко Н.Н. Мукормикоз на фоне COVID-19: описание клинического случая и обзор литературы // Клиническая микробиология и антимикробная химиотерапия. 2021. Т. 23, № 3. С. 255–262. [Khostelidi S.N., Zaytsev V.A., Pelikh E.V., Yashina E.V., Rodionova O.N., Bogomolova T.S., Avdeenko Yu.L., Klimko N.N. Mucormycosis following COVID-19: clinical case and literature review. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy, 2021, vol. 23, no. 3, pp. 255–262. (In Russ.)] doi: 10.36488/cmac.2021.3.255-262
- Чеботарь И.В., Поликарпова С.В., Бочарова Ю.А., Маянский Н.А. Использование времяпролетной масс-спектрометрии с матрично-активированной лазерной десорбцией/ионизацией (MALDI-TоF MS) для идентификации бактериальных и грибковых возбудителей III–IV групп патогенности // Лабораторная служба. 2018. Т. 7, № 2. С. 78–86. [Chebotar I.V., Polikarpova S.V., Bocharova Yu.A., Mayansky N.A. Use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-ToF MS) for identification of bacteria and fungi of the pathogenicity group III and IV. Laboratornaya sluzhba = Laboratory Service, 2018, vol. 7, no. 2, pp. 78–86. (In Russ.)] doi: 10.17116/labs20187278-86
- Щелканов М.Ю., Колобухина Л.В., Бургасова О.А., Кружкова И.С., Малеев В.В. COVID-19: этиология, клиника, лечение// Инфекция и иммунитет. 2020. Т. 10, № 3. С. 421–445. [Shchelkanov M.Yu., Kolobukhina L.V., Burgasova O.A., Kruzhkova I.S., Maleev V.V. COVID-19: etiology, clinical picture, treatment. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2020, vol. 10, no. 3, pp. 421–445. (In Russ.)] doi: 10.15789/2220-7619-CEC-1473
- Bhatt K., Agolli A., Patel M.H., Garimella R., Devi M., Garcia E., Amin H., Dominigue C., Del Castillo R.G., Sanchez-Gonzalez M. Hight mortality co-infection of COVID-19 patients: mucormycosis and other fungal infections. Discoveries, 2021, vol. 9, no. 1: е126. doi: 10.15190/d.2021.5
- Burton C., Fink P., Henningsen P., Löwe B., Rief W., EURONET-SOMA Group. Functional somatic disorders: discussion paper for a new common classification for research and clinical use. BMC Medicine, 2020, vol. 18, no. 1: e34. doi: 10.1186/s12916-020-1505-4
- Fernández-García O., Guerrero-Torres L., Roman-Montes C.M., Rangel-Cordero A., Martínez-Gamboa A., Ponce-de-Leon A., Gonzalez-Lara M.F. Isolation of Rhizopus microsporus and Lichtheimia corymbifera from tracheal aspirates of two immunocompetent critically ill patients with COVID-19. Med. Mycol. Case Rep., 2021, vol. 33, pp. 32–37. doi: 10.1016/j.mmcr.2021.07.001
- Hernández J.L., Buckley C.J. Mucormycosis: StatPearls Publishing; Last update: april 30, 2022. URL: https://www.ncbi.nlm.nih.gov/books/NBK544364 (23.05.2022)
- Ibrahim A.S., Spellberg B., Walsh T.J., Kontoyiannis D.P. Pathogenesis of mucormycosis. Clin. Infect. Dis., 2012, vol. 54, suppl. 1 (suppl. 1), pp. S16–S22. doi: 10.1093/cid/cir865. doi: 10.1093/cid/cir865
- Katragkou A., Walsh T.J., Roilides E. Why is mucormycosis more difficult to cure than more common mycoses? Clin. Microbiol. Infect., 2014, vol. 20, suppl. 6, pp. 74–81. doi: 10.1111/1469-0691.12466
- Lin E., Moua T., Limper A.H. Pulmonary mucormycosis: clinical features and outcomes. Infection, 2017, vol. 45, no. 4, pp. 443–448. doi: 10.1007/s15010-017-0991-6
- Pan J., Tsui C., Li M., Xiao K., de Hoog G.S., Verweij P.E., Cao Y., Lu H., Jiang Y. First case of rhinocerebral mucormycosis caused by Lichtheimia ornata, with a review of Lichtheimia infections. Mycopathologia, 2020, vol. 185, no. 3, pp. 555–567.
- Pasero D., Sanna S., Liperi C., Piredda D., Branca G.P., Casadio L., Simeo R., Buselli A., Rizzo D., Bussu F., Rubino S., Terragni P. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection, 2021, vol. 49, no. 5, pp. 1055–1060. doi: 10.1007/s15010-020-01561-x
- Reid G., Lynch J.P., Fishbein M., Clark N.M. Mucormycosis. Semin. Respir. Crit. Care Med., 2020, vol. 41, no. 1, pp. 99–114. doi: 10.1055/s-0039-3401992
Supplementary files
